前列腺癌的免疫治疗研究进展

打开文本图片集

Research advances in immunotherapy for prostate cancer

NIU Yuanjie，YU Jianpeng，WANG Keruo （Department of Urology，The Second Hospital of Tianjin Medical University，Tianjin ）

ABSTRACT：Immunotherapy has demonstrated significant eficacyin hematologic malignancies andcertain solid tumors，but its efficacy forprostatecancerremains suboptimal.This is largelydue to theimmunosuppresive tumor microenvironment， which involves factors such as tumor heterogeneitya paucityof infiltrating lymphocytes，and the absenceof inflammatory features.Therefore，developing novelimmunotherapeutic targetsandcombining multipleimmunotherapymodalies toactivate the host immune system andreverse the immunosuppesive tumor microenvironmentare crucialforimproving immunotherapy for prostatecancer.This reviewsystematicallysummarizes thecurrentresearchonprostatecancer immunotherapycoverig the chalenges andadvancesof prostatecancervaccines，theapplicationof immunecheckpointinhibitors，targeted therapeutic strategies involvingchimericantigenreceptorTcels，bispecificantibodies，andemerging strategiesinprostatecancer immunotherapy.Furthermore，the review discuses thefuture directions for the development of prostate cancer immunotherapy.

KEY WORDS： prostate cancer; immunotherapy；cancer vaccine;immune checkpoint inhibitor

中图分类号：R737.2 文献标志码：A DOI：10.3969/j.issn.1009-8291.2025.08.001

前列腺癌在美国男性恶性肿瘤中发病率居首位，死亡率居第2位。（剩余19791字）